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Abstract 
Abnormal fatty acid metabolism and availability are landmarks of metabolic diseases, 
which in turn are associated with aberrant DNA methylation profiles. To understand the 
role of fatty acids in disease epigenetics, we sought DNA methylation profiles 
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specifically induced by arachidonic (AA) or oleic acid (OA) in cultured cells and 
compared those with published profiles of normal and diseased tissues. THP-1 
monocytes were stimulated with AA or OA and analyzed using Infinium 
HumanMethylation450 BeadChip (Illumina) and Human Exon 1.0 ST array (Affymetrix). 
Data were corroborated in mouse embryonic fibroblasts. Comparisons with publicly 
available data were conducted by standard bioinformatics. AA and OA elicited a 
complex response marked by a general DNA hypermethylation and hypomethylation in 
the 1-200 μM range, respectively, with a maximal differential response at the 100 μM 
dose. The divergent response to AA and OA was prominent within the gene body of 
target genes, where it correlated positively with transcription. AA-induced DNA 
methylation profiles were similar to the corresponding profiles described for palmitic 
acid, atherosclerosis, diabetes, obesity, and autism, but relatively dissimilar from OA-
induced profiles. Furthermore, human atherosclerosis grade-associated DNA 
methylation profiles were significantly enriched in AA-induced profiles. Biochemical 
evidence pointed to -oxidation, PPAR-alpha, and sirtuin 1 as important mediators of 
AA-induced DNA methylation changes. In conclusion, AA and OA exert distinct effects 
on the DNA methylome. The observation that AA may contribute to shape the 
epigenome of important metabolic diseases, supports and expands current diet-based 
therapeutic and preventive efforts. 
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Introduction 
An organism’s fatty acid (FA) pool reflects both composition of the diet and 
endogenous synthesis. Furthermore, abnormal FA levels have long been recognized to 
participate in metabolic diseases such as diabetes.1 Since metabolic diseases are 
frequently associated with aberrant DNA methylation profiles2, it is conceivable that 
FAs are among factors that mediate remodeling of the epigenome in response to 
dietary composition, the cell’s metabolic status and pathogenic signals. In humans, 
only a handful of studies have investigated a link between DNA methylation and fat 
intake, focusing on specific genes associated with FA metabolism, inflammation and 
regulation of circadian rhythms.3–8 Furthermore, a recent genome-wide study 
comparing peripheral whole blood methylation profiles to both quantity and quality of 
dietary fat intake in adolescents, found a larger number of methylation changes 
associated with the latter.9 In that study, DNA methylation profiles associated with 
polyunsaturated:saturated FA ratio were related to pathways regulated by the 
peroxisome proliferator-activated receptor  (PPAR-) and adipogenesis. Conversely, 
no pathways were identified of DNA methylation profiles associated with the 
monounsaturated:saturated FA ratio. In addition, numerous mouse model studies have 
addressed short and long term epigenetic effects of diets containing variable 
combinations of specific FAs.8,10 
Although diet-based studies are important as they recognize the complexity of the 
organism's response to nutrients, mechanistic insights can be gained by a simplified 
complementary approach based on the manipulation of individual FA levels. 
Accordingly, the effects of short FAs, such as butyrate, on DNA methylation have been 
long recognized.11 In addition, very low-density lipoprotein (VLDL) elicited a global DNA 
hypermethylation response that is markedly stronger than the one induced by low- or 
high-density lipoprotein in cultured human THP-1 macrophages.12,13 The fact that VLDL 
is characteristically rich in triglycerides suggests that FAs might be mediators of the 
epigenetic responses to VLDL. Accordingly, arachidonic acid (AA) induces DNA 
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hypomethylation in human umbilical vein endothelial cells at 3 μM concentration, 
globally and of angiogenesis regulator kinase insert domain receptor gene 
promoter.14,15 Another study demonstrated that 100 μM eicosapentaenoic acid (EPA) 
directly modifies the methylation status of CCAAT / enhancer-binding protein delta 
gene.16 As for cellular disease models, palmitic acid (PA) was shown to induce global 
DNA hypermethylation in primary human myocytes and ex vivo human pancreatic islet 
cells at a 500 μM and 1 mM dose, respectively, affecting targets such as the PPAR- 
co-activator 1A gene.17,18 Furthermore, a recent study in a cellular model of hepatic 
cancer has shown that a mixture of oleic acid (OA) and PA elicits hypermethylation of 
selected imprinted gene promoters.19 Possible mechanisms of epigenetic regulation by 
FAs include binding to PPARs, a family of transcription factors that regulate numerous 
metabolic processes via ligand-dependent transcriptional activation and repression.20,21 
Currently, it is unknown whether the above-described epigenetic effects are FA-
specific, as is the contribution of FAs to disease-related methylation profiles. To 
understand those issues, we focused on the two long-chain unsaturated FAs, OA and 
AA, which are known to exert generally opposite cellular inflammatory responses.22–24 
We studied the effects of these particular FAs on the epigenome and transcriptome of 
THP-1 cells, a widely accepted human monocyte model25, and compared our results to 
available DNA methylation data of several human diseases and normal tissues. The 
implications of our results are discussed in the context of current knowledge of 
epigenetic regulation by lipid components and dietary factors, and their contribution to 
disease risk. 
Results 
Effects of the pure AA and OA on global DNA methylation in cultured cells 
We first examined the effects of the pure FAs, AA, and OA, on global DNA methylation,  
i.e., total normalized 5mdC content in cultured human THP-1 monocytes. Stimulation 
experiments were carried out for 24 hours using FAs in the 0-200 μM concentration 
range. These concentration are below or within the reported circulating FA range—see, 
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for example, Higashiyama et al.26 The rationale for using a 24-hour stimulation is that 
epigenetic responses to lipoproteins were observed in THP-1 macrophages, a 
differentiated version of THP-1 monocytes.12,13 In accordance with a similar study of 
AA-stimulated THP-1 cells, where cell proliferation was scored based on 3H-thymidine 
incorporation27, FAs did not affect cell proliferation as assessed by cell counting. 
Overall, AA and OA elicited distinct responses. AA induced a dose-dependent DNA 
hypermethylation peaking at the 100 μM dose and amounting to a ~10.5% increase in 
5mdC content at 100 μM relative to the 1 μM dose (Figure 1A). In turn, OA induced a 
weaker response, with an overall DNA hypomethylation at 100 μM relative to the 1 μM 
dose. Noticeably, the effect of OA was significantly different from the one of the vehicle 
BSA only at doses >100 μM. Neither OA nor BSA elicited statistically significant 
responses relative to unstimulated cells or cells stimulated with the 1 μM of any FA, up 
to the 50 μM dose. To validate the divergent AA and OA dose responses, a 24-hour 
co-stimulation experiment, in which one FA was held constant at 100 μM concentration 
while the other varied between 1-100 μM, was performed. The results confirmed the 
distinct DNA methylation responses to AA and OA in THP-1 cells [Figure 1B; note that 
the respective responses at 100 μM were not different (P=0.08)]. Importantly, the 
observed AA- and OA-induced DNA methylation changes were not specific for THP-1 
monocytes, as human embryonic kidney 293 cells also displayed distinct responses to 
these FAs following a 24-hour stimulation (Supplementary Figure 1). These 
experiments were exhaustively repeated and their results were consistent across time 
(2004-2013), cell culture laboratories, and THP-1 cell stocks (Sweden, Mexico, and 
Spain for either), HPLC platforms (Mexico and Spain), and total 5mdC assays (HPLC-
based or the ELISA-based MethylFlash system). 
 As an independent validation of the total 5mdC data, we performed an ALU-
specific methylation assay. ALUs are an abundant transposon family and have often 
been used as a surrogate of total 5mdC determination.28 In accordance with total 5mdC 
data, AA induced a significant dose-dependent increase in ALU methylation while OA 
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showed a tendency to hypomethylation, although not statistically significant in the 1-
100 μM range (Figure 1C). 
Effects of AA and OA on specific CpG site methylation 
To detail genomic regions undergoing FA dose-dependent differential DNA methylation 
at the CpG level resolution, we analyzed THP-1 monocytes stimulated with 1, 10, or 
100 μM AA or OA, using the Infinium HumanMethylation450 BeadChip arrays (450K 
array). The platform represents >485,000 intergenic and intragenic, non-repeated 
element CpGs.29,30 The rationale for using 100 μM as maximal dose was that it yielded 
the most divergent effects between the two FAs in the total 5mdC assay. 
 Unsupervised clustering analysis of 450K array data showed that the FA-
induced methylation profiles were more divergent at 100 μM FA dose compared to the 
relatively similar 1 and 10 μM-dose profiles (Figure 2), mirroring global 5mdC data 
(compare with Figure 1A). Next, we sought evidence for an AA dose-dependent DNA 
hypermethylation response and an opposite one for OA in 450K array data. We 
restricted our analysis to cells challenged with increasing—1, 10 and 100 μM—FA 
doses, as the unstimulated cell data reflect a non-physiological FA-free situation. A 
further reason for not including BSA-stimulated cells in the 450K array analysis, was 
that global 5mdC data indicated that the global trend of OA-induced DNA 
hypomethylation was statistically different from the corresponding BSA data set. Before 
conducting a detailed analysis of the 450K array data, we validated the methylation 
profiles of 11 CpGs corresponding to 6 genes by pyrosequencing. Genes were 
randomly selected among CpGs with absolute >0.1 between 1-100 μM AA. In all 
cases, pyrosequencing reproduced the DNA methylation profile of the 7 CpGs 
represented on the 450K array and additional flanking 4 CpGs (Supplementary 
Figure 2). Subsequently, we sought autosomal CpGs that showed dose-dependent 
DNA methylation profiles, i.e., CpGs with statistically significant FA dose-dependent 
DNA methylation changes. We initially set a Δβ>0.2 between the extreme 1 and 100 
μM FA doses as a stringent criterion to identify FA dose-dependent profiles. Such a 
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filtering yielded 283 and 135 CpGs for AA and OA, respectively, a figure that is 
inconsistent with the global 5mdC data shown above. We therefore reasoned that FAs 
imposed small and widespread CpG methylation changes. Consequently, CpGs 
displaying an absolute Δβ>0.005 between consecutive FA doses (i.e., with absolute 
Δβ>0.01 between the extreme 1 and 100 μM FA doses) were considered for further 
analysis. We first separated the CpG sets for each FA into two subsets that displayed a 
positive or negative Δβ between extreme FA doses, and performed a Spearman's 
correlation test separately on the CpGs subsets. This allowed us to perform a one-
tailed test using an absolute r>0.985 threshold value corresponding to P<0.05, for each 
subset. Those CpGs will be referred to as AACpGs or OACpGs. The analysis identified 
57,187 AACpGs and 48,917 OACpGs, corresponding to 14,483 and 13,914 genes, 
respectively (a complete list of AACpGs and OACpGs can be provided upon request). 
The absolute Δβs between 100 and 1 μM FA doses ranged between 0.29-0.01 for the 
two sets compounded. None of the AACpGs or OACpGs reached the genome-wide 
significance threshold of P<10-7. A minority of AACpGs (6,432 or 11.2%) overlapped 
with OACpGs, corresponding to 3,722 genes. 
Biological significance of AACpGs and OACpGs 
Although the AA- and OA-induced differential methylation did not reach genome-wide 
significance, a substantial number of converging findings support a pathobiological 
significance for AACpGs and OACpGs.  
First, in agreement with global DNA methylation data, a general tendency for AA-
induced hypermethylation and OA-induced hypomethylation was observed, i.e., the 
majority of AACpGs (76.4%) and OACpGs (74.7%) showed dose-dependent hyper- 
and hypo-methylation, respectively (P=6.7x10-32, Chi-square test; Figure 3). Likewise, 
the compounded weight of hypermethylated AACpGs was higher than the 
hypomethylated counterparts: the sum of Δβs between 100 and 1 μM AA was 1,661.3 
and -408.7 for the two sets, respectively. Conversely, the net effect of OACpGs was 
hypomethylation, since the sum of Δβs between 100 and 1 μM OA was 381.6 and -
 9 
 
1,308.7 for the hyper- and hypo-methylated OACpG set, respectively. This overall 
divergent DNA methylation profile included the 6,432 common CpGs between the 
AACpG and OACpG sets, as the M values between 100 and 1 μM FA doses showed a 
negative correlation between the two sets (r=-0.14, P<10-6). 
Second, at the gene level, most AACpGs and OACpGs co-localized to gene 
bodies and promoters and, at the same time, were remarkably divergent for the 
direction of DNA methylation change. For all overlapping genes, AACpG and OACpGs 
showed hyper- and hypo-methylation, respectively, between extreme FA doses (P<10-5 
in all cases). This tendency was particularly evident of genes that harbored >50 
AACpG or AOCpG/gene, which included protein tyrosine phosphatase, receptor type, 
N polypeptide 2 (PTPRN2), mitotic arrest deficient-like 1 (MAD1L1), PR domain 
containing 16 (PRDM16), tenascin-XB (TNXB), regulatory-associated protein of mTOR 
(RPTOR), inositol-1,4,5-trisphosphate 5-phosphatase (INPP5A), adenosine 
deaminase, RNA-specific, B2 (ADARB2), sidekick cell adhesion molecule 1 (SDK1), 
ATPase, class VI, type 11A (ATP11A), tubulin folding cofactor D (TBCD), and disco-
interacting protein homolog 2 (DIP2C). Furthermore, such divergence in FA-specific 
methylation profiles was also observed of at least two large intergenic regions 
spanning 605.7 kb and 758.0 kb in size on chromosome 4 and 8, respectively. Figure 
4 shows illustrative examples of reciprocal AA- or OA-induced methylation profiles of 
three genes that showed more >50 AACpG or AOCpG/gene and of the intergenic 
region on chromosome 8. All, or only overlapping AACpGs and OACpGs, are shown 
(left and right panels, respectively). 
Third, functional annotation analysis using the top 150 genes ranked by number 
of differentially methylated AACpG and OACpGs, normalized by the number of probes 
present in the 450K array for a given gene (N-CpGs), revealed significant enrichments 
for the G protein-coupled receptor (GPCR) and olfactory signaling pathways 
(REACT_14797 and hsa04740, respectively; Supplementary Table 1). Conversely, no 
signaling pathways were identified for the top 150 genes ranked by Δβ (DB-CpGs) 
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(Supplementary Table 1). Remarkably, functional gene analysis of differentially 
expressed genes between 100 and 1 μM AA and OA doses revealed a significant 
enrichment of the same GPCR signaling pathway (FDR<10-4 in both cases; see 
paragraph below ―FA-induced CpG methylation and gene expression‖). Notably, the 
average absolute Δβ value of the top 150 N-AACpG and N-OACpGs were ~4-fold 
smaller relative to DB-AACpG and DB-OACpGs (0.045 and 0.041 versus 0.174 and 
0.161 on average, respectively; Supplementary Table 2), again pointing to small but 
biologically relevant effects. 
Fourth, we compared AACpG or OACpG to a study addressing the effects of 
PA on the DNA methylome of primary human pancreatic islets, a model of pro-
inflammatory free FA-induced diabetes.18 Notably, reminiscent of the effects of AA in 
THP-1 monocytes, PA induces a net DNA hypermethylation relative to pancreatic islets 
stimulated with FA-free BSA alone. In a first instance, we asked whether any 
differentially methylated CpGs were shared by the two studies, i.e., the dose-
dependent AACpGs and OACpGs, and PA-induced differentially methylated CpGs 
(PACpGs). Remarkably, despite significant experimental design differences between 
the PA-stimulated pancreatic islet model and AA- or OA-stimulated THP-1 cells, 
including FA concentration (1 mM and 1-100 μM range), incubation time (48 and 24 
hours) and cell type (pancreatic islets and THP-1 monocytes), a 10-12% overlap 
between CpGs was observed. A total of 445 CpGs corresponding to 430 genes, were 
common to the AACpG, OACpG and PACpG datasets (referred to as FACpGs; 
Supplementary Table 3). A functional annotation analysis revealed a significant 
enrichment for regulation by a number of transcription factors, including the biologically 
plausible CCAAT/enhancer binding protein (C/EBP), alpha (CEBPA), a critical activator 
of adipocyte-specific genes (FDR=8.2x10-7) and PPAR- (FDR=0.03), but not the 
related PPAR- (FDR=0.33).31,32 Furthermore, we found that the M-values between 
AACpGs and PACpGs were positively correlated (r=0.21, P=1.20x10-5) and the 
majority (72.8%) were hypermethylated in both sets. Conversely, no correlation 
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between the OACpGs and PACpGs was observed (r=0.08, P=0.10) and the majority 
(70.3%) of FACpGs were hypo- and hyper-methylated in the two sets, respectively. 
Furthermore, akin to AA and OACpGs, functional analysis of the top 150 normalized 
(number of differentially methylated CpG divided by the number of probes in the 450K 
array) PACpGs revealed enrichment in G-protein and olfactory signal transduction 
pathways (Supplementary Table 1). These data suggested a functional divergence 
between AA and PA on the one hand, and OA on the other hand with respect to DNA 
methylation. 
The analogies between FA-stimulated THP-1 cells and a model of pancreatic 
inflammation raised the question whether similar coincidences exist within a range of 
human diseases. To address that issue, we compared AACpGs and OACpGs to the 
450K array-based human DNA methylation profiling datasets that were available to 
date. These datasets covered a wide range of disease typology and conditions, i.e., 
metabolic diseases (atherosclerosis, obesity, type 2 diabetes)33–35, psychiatric 
disorders (autism—Brodmann areas 10 and 24 profiling—and schizophrenia)36,37, 
cancer (leukemia, colorectal carcinoma, hepatocellular carcinoma, blood from breast 
cancer patients),38–41 and aging42 (Supplementary Table 4). The inclusion of the 
mentioned studies is justified by the general relevance of FAs as suppliers of energy 
and biologically active metabolites, and their recognized involvement in psychiatric 
disorders (reviewed in43). In addition, the comparative analysis included 450K array-
based DNA methylation profiles of eight non-diseased tissues.44 The portion of 
differentially methylated CpGs identified in each study, that overlapped AACpG or 
OACpGs ranged between 12-17%. Furthermore, despite differences in Δβ cut-off 
between arrays (Supplementary Table 4) we observed no significant correlation 
between the extent of overlap and Δβ cut-off values. Excluding the breast cancer blood 
dataset, which did not represent the disease target tissue, we observed a notably lower 
overlap in cancer compared to metabolic, psychiatric and normal tissue sets (P<0.01 in 
all comparisons, Scheffé post-hoc test; aging was not included in the analysis given 
 12 
 
that it represented a single study). Since we found no correlation between extent of 
overlap and number of differentially methylated CpGs yielded by each study (r=-0.12, 
n=20, P=0.62), our data suggested a non-random overlap despite the relatively high 
number of AACpGs and OACpGs. Gene function analysis for the top 150 N-CpG-
harboring genes revealed a common significant enrichment in the GPCR signaling 
pathway among the cancer and autism (BA24) profiles (FDR<10-2 in all cases), but not 
in normal tissue samples, suggesting an underlying biological specificity (in italics in 
Supplementary Table 1). 
Next, we compared the methylation state of AACpGs and OACpGs to that of 
differentially methylated CpGs identified in diseased or normal tissue. Clustering 
analysis of CpG methylation levels (Δβ) averaged by gene, clearly showed that the AA- 
and PA-induced profiles were more similar to each other than to OA-induced profiles. 
Furthermore, the former clustered with metabolic disease, aging and autism profiles, 
whereas cancer, schizophrenia and normal tissue-specific profiles grouped away from 
FAs (Figure 5A). These patterns were readily observed in the clustering analysis of the 
top 50 genes, ranked by the number of overlapping CpGs (Figure 5B). For example, 
the majority of genes were consistently hypermethylated following stimulation with AA 
or PA but hypomethylated following stimulation with OA. The top 50 genes included all 
of the genes harboring >50 AACpG/gene (see above), three of which ranked highest in 
both lists, i.e., PRDM16, PTPRN2, and MAD1L1. 
Fifth, we asked whether AACpGs significantly overlap with a set of 450K array 
methylation profiles obtained in human aortic atherosclerotic lesions of varying 
histological severity.45 That study identified 1,985 autosomal CpGs, which significantly 
change their methylation status with lesion progression (grade-CpGs), mostly by 
drifting towards hypermethylation as lesion grade increases. Grade-CpGs were 
significantly enriched in AACpGs, as 510 CpGs overlapped between the two sets and 
324 showed the same methylation trend, mostly (311 out of 324) towards 
hypermethylation both in response to increasing AA doses and with lesion progression 
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(P=0.011 for enrichment, hypergeometric test). A list of the 324 overlapping and 
concordant CpGs between the two sets is shown in Supplementary Table 5. 
Sixth, AA- and OA-induced DNA methylation profiles showed a degree of 
specificity for sequences with specific epigenetic and functional signatures. As for 
preference for hypo- or hyper-methylated sequences, we analyzed the distribution of 
the AACpG and OACpG across-values. We observed a clear enrichment of the 
initially hypermethylated group, i.e., at 1 μM FA dose for both AACpGs and OACpGs, 
that was independent of the direction of methylation change (Supplementary Figure 
3). As for gene compartments and GC content, hypermethylated AACpGs preferentially 
mapped to sites within open sea (i.e., >4 kb from the nearest CpG island), whereas 
hypomethylated AACpGs mapped preferentially to CpG islands (P=0.031 and P=0.009, 
respectively, compared to the 450K array probe distribution; Supplementary Figure 
4). No other CpG set showed any significant mapping preference. 
Overall, these findings support a broad biological significance and instructive 
mechanism(s), rather than random seeding, for the overall comparatively small AA- 
and OA-induced DNA methylation profiles. 
FA-induced CpG methylation and gene expression 
To assess the impact of dose-dependent changes in DNA methylation on gene 
expression, RNA was extracted from the same cells used to produce 450K array data 
and analyzed using the Affymetrix Human Exon 1.0 ST platform. To probe for an 
association between expression and DNA methylation, we focused on AACpGs and 
OACpGs that colocalized to exonic regions, i.e., 23,436 and 18,591 CpGs, 
respectively. Of the latter, we correlated the dose-dependent changes in DNA 
methylation with the corresponding changes in expression values for each exon probe 
(Figure 6A). While DNA methylation changes in any genomic context showed both 
positive and negative associations with transcription, context-dependent correlations 
were uncovered; in particular, a negative correlation in the promoter, 5’UTR and first 
exon and a positive correlation within gene body and 3’UTR regions. Importantly, 
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average exonic Δβ values between the 100 and 1 μM FA dose were higher of AACpGs 
compared to OACpGs (0.023 and -0.021, respectively). Since this mirrored the overall 
tendency of all AACpG and OACpGs, we concluded that gene body methylation was 
more frequently associated with an increase, rather than a decrease, in transcription. 
RT-PCR analysis of genes that showed a high number of opposite dose-dependent 
changes in DNA methylation following stimulation with AA and OA, also supported a 
tendency for a positive association between gene body methylation and expression for 
some of the genes analyzed (Figure 6B,C). Furthermore, functional gene analysis 
revealed a significant enrichment in GPCR signaling (FDR<10-4 in both cases), 
mirroring the functional enrichment observed in FA-induced methylation profiles (see 
above). 
Factors mediating FA-induced changes in DNA methylation 
To explore potential mechanisms underlying AA- and OA-induced changes in DNA 
methylation, we focused on PPAR- and PPAR-, given that both are expressed in 
THP-1 cells and that FAs, or derivatives thereof, are known ligands of these nuclear 
receptors.46,31 First, because the above presented functional annotation data suggested 
a potential role for PPAR-, but not PPAR- in regulating FACpG methylation and, 
second, due to the link between G-protein cannabinoid receptor signaling pathway and 
PPAR- transcription pathway,47,48 we examined the effects of the PPAR- and PPAR-
 antagonists GW6471 and GW9662, respectively, on the FA-induced methylation 
responses. GW6471, significantly and substantially, inhibited global DNA 
-dependent fashion, while no 
effect was observed in cells stimulated with OA (Figure 7A,B). As for GW9662, neither 
AA- nor OA-induced methylation responses were significantly affected. Carnitine 
palmitoyltransferase-1 (CPT1), an enzyme that regulates the import of long-chain FA 
transport into the mitochondria, is a known target of PPAR- PPAR- 
antagonist, etomoxir, an inhibitor of CPT1, significantly inhibited global DNA 
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-dependent fashion (Figure 
7A), while no significant effect of cells stimulated with OA was observed (Figure 7B). 
Numerous data lend support to complex interactions between PPARs and 
sirtuins, the latter of which also regulate transcriptional networks of critical metabolic 
processes via their NAD+ dependent histone deacetylase activity.49 To understand 
whether sirtuins played a role in the FA methylation responses, mouse embryonic 
fibroblasts (MEFs) obtained from SIRT1-, SIRT2-, or SIRT6-null mice and their 
These particular sirtuins were chosen due to their facultative or preferential nuclear 
location and prior evidence for their regulatory roles in FA oxidation (reviewed in49). 
Importantly, both AA and OA elicited methylation responses in WT MEFs, which were 
comparable to those observed in human THP-1 cells. However, among the analyzed 
mutant MEFs, AA-, and OA-specific DNA methylation responses were only significantly 
inhibited in SIRT1-null cells (Figure 8A). As further validation of SIRT1 participation in 
AA-induced hypermethylation, we examined the effects of SIRT1 inhibitors, sirtinol and 
splitomycin, in THP-1 monocytes. Both inhibitors led to reduced levels of DNA 
deacetylase inhibitor with a preference for non-NAD+ dependent histone deacetylases, 
failed to elicit any effects (Figure 8B). 
Discussion 
We have uncovered distinct DNA methylation profiles induced by AA and OA, two 
unsaturated FAs generally known for their pro-inflammatory and anti-inflammatory 
properties, respectively. Our global, ALU-specific and individual CpG methylation data 
obtained in various laboratories across a long period of time (see Results), consistently 
show divergent effects of the two FAs in the analyzed dose range, i.e., AA and OA 
induce DNA hypermethylation and hypomethylation, respectively, both in human and 
mouse cultured cells. A comparative analysis of publicly available human DNA 
methylome data, further confirm the biological relevance of these findings, despite the 
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different criteria used to identify relevant CpG loci. The pro-inflammatory FAs AA and 
PA induce markedly similar DNA methylation profiles, compared to the corresponding 
OA-induced profiles. Yet, FA-induced methylation and expression profiles are both 
enriched in the GPCR signaling function, suggesting antagonistic effects on common 
cellular pathways. Those similarities are further supported when comparing FA-induced 
profiles with disease- and normal tissue-specific corresponding data. AA and PA 
cluster together with metabolic diseases (atherosclerosis, obesity, type 2 diabetes), 
aging, and autism. OA, on the other hand, clusters more weakly with the latter 
conditions. This clustering therefore closely reflects the known distinct pathobiological 
properties of AA and PA on the one side, and OA in the other. Furthermore, several of 
the identified target genes are relevant from a nutritional and evolutionary perspective. 
For example, a 12-week supplementation with AA and DHA in baboons is associated 
with downregulation of PTPRN2 in the cerebral cortex.50 Likewise, an association 
between DNA methylation, a sequence variant of PTPRN2 and islet insulin secretion 
has also recently been identified.51 In turn, TNXB is one of the two genes showing 
population-specific polymorphisms associated with dietary adaption to fat, milk, and 
meat.52 These associations, although independent and converging, are not definite 
proof of causality. Also, the effects of FAs presented here are quantitatively modest, 
reflecting the 10% or less change in DNA methylation profiles that was detected in 
response to FA, high-fat diet and exercise.18,53,54 Despite these limitations, the data 
provide testable hypotheses to better understand the regulation of the DNA methylome 
by FAs and possibly to improve diet-based strategies to improve human health. 
 These comparisons offer a number of insights into the pathophysiological 
relevance of the epigenetic responses to FAs. In the case of human atherosclerosis, 
we show concordance with two previously published studies. First, the histological 
grade-associated CpGs45 are significantly enriched in AACpGs. Second, 16 of the most 
represented genes across the analyzed DNA methylation profiling studies, are densely 
hypermethylated in the early stages of the aortic atherosclerosis and display a direction 
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of DNA methylation change that is concordant with the one of AA and PA.33 In both 
atherosclerosis and AA-stimulated cells, hypermethylation is prominent within the body 
of these genes. Taken together, these comparative data suggest that a portion of the 
DNA hypermethylation that characterizes atherosclerosis in its initial phases and during 
the progression of the stable vascular lesion33,45, may be seeded by circulating pro-
inflammatory FAs or their metabolites. Coupled with evidence that hypomethylating 
agents can slow the progression of the vascular lesion55, our observations may lead to 
testable nutritional strategies to reprogram or safeguard the vascular epigenome. As 
for autism, the involvement of AA in that condition has been established by early 
prospective studies documenting the effects of AA-depleted infant formulas on autism 
risk and by a recent comparative study of red blood cell AA content between autistic 
patients and controls.56,57 Another finding of our study is the divergence of type 2 
diabetes DNA methylation profiles from the ones of AA and, notably, PA. The 
hypermethylated loci identified in both AA- and PA-stimulated cells show a distant, if 
any, resemblance to the corresponding profiles in diabetes, thus revealing a set of 
CpGs that do not model the involvement of free pro-inflammatory FAs in diabetes. 
Additionally, we show that FA-induced profiles are relatively distant from normal tissue-
specific ones. This result is expected, as due to the ubiquitous access of circulating 
FAs to organs and tissues, it is likely that FAs seed DNA methylation profiles that 
represent common features of the majority of the organism´s epigenomes. Incidentally, 
our findings confirm and expand the previous observation that normal blood displays a 
strikingly unique DNA methylation profile, compared to the other tissues and diseases 
tested.44 In addition to all these considerations, it is noteworthy that the specificity of 
the overlap with a number of published studies constitutes a powerful independent 
validation of our 450K array-based results.  
Pathways linked to -oxidation play a pivotal role in determining FA-related 
methylation profiles. We show that AA-induced DNA hypermethylation is sensitive to 
inhibition of FA import to mitochondria and is downstream to PPAR- and SIRT1, two 
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central regulators of FA metabolism and -oxidation.48 THP-1 monocytes, in contrast to 
cancer cells in general, rely more on -oxidation than glycolysis for energy production 
and AA has been shown to be a substrate for -oxidation in THP-1 cells.58,59 Both these 
observations support the effects of -oxidation inhibition in our model system. Indeed, 
the comparatively small overlap between cancer and FA-induced DNA methylation 
profiles may be explained by the Warburg effect which states that cancer cells mainly 
produce ATP from glycolysis even in conditions of hypoxia.60 Following this logic, the 
DNA hypomethylation observed in diabetes is a predictable consequence of the 
defective mitochondrial activity associated with that disease.61 In general, blockage of 
the mitochondrial machinery rapidly shifts ATP production to glycolysis to assure cell 
survival. We assume that such an adaptation takes place in THP-1 cells following 
exposure to -oxidation inhibitor etomoxir, suggesting that inhibition of AA-induced 
DNA hypermethylation by etomoxir does not result from reduced ATP supply to 
chromatin modifiers. On the other hand, the OA-induced hypomethylation response is 
not affected by these inhibitors. This suggests that the distinct AA and OA-induced 
methylation profiles might relate to FA-specific differences in -oxidation. Indeed, both 
in vitro and a recent in-vivo dietary study in humans show that OA relative to other FAs, 
such as PA and EPA, is a poor substrate of -oxidation62–64, although the opposite has 
also been reported.65 Alternatively, the increased levels of specific intermediate -
oxidation products observed in PA- relative to OA-stimulated human skeletal muscle 
cells could also explain part, or all of, the PA-induced methylation.62 Although our data 
contrast with the predominant view that SIRT1 is activated solely in condition of 
starvation, NAD+ independent SIRT1-mediated upregulation of oxidative metabolism 
has been reported in several other studies.66–68 Finally, the observation that SIRT1 
participates in the AA-induced DNA hypermethylation response in MEFs, indicates that 
the corresponding response observed in THP-1 cells is not a cancerous cell-restricted, 
p53- and MIR34a-dependent event.69 
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The PPAR- specific regulation of AA-induced DNA methylation, presumably 
reflects the observation that polyunsaturated FAs are more potent activators of PPAR-
 than PPAR-.70 The involvement of PPAR-, but not PPAR-, is further supported by 
the results of the functional annotation analysis of FACpG-harboring genes. SIRT6 can 
also be activated by long-chain FAs, in particular OA, and contributes to regulation of 
-oxidation.71,72 However, knockdown of SIRT6 in MEFs had no effect on FA-induced 
changes in DNA methylation. 
Our observation that AA and OA participate in shaping metabolic disease-
specific DNA methylomes through -oxidation, PPAR-  and sirtuin 1 signaling, has 
potential implications for diet-oriented therapy and prevention. Indeed, it has been 
argued that the high-fat, low-carbohydrate ketogenic diet, which is successful in clinical 
management of patients with inborn errors of metabolism and pharmacoresistant 
epilepsy, may be beneficial in a much broader range of diseases than previously 
recognized.73,74 Conversely, a low-fat, low-carbohydrate diet can lead to normalization 
of  cell function and insulin resistance in individuals with type 2 diabetes.75 However, 
whether or not a shift in substrate preference toward fat oxidation lowers disease risk is 
still heavily debated. For example, prolonged dietary administration of the PPAR- 
agonist WY-14643, is associated with a gradual decreased in global and LINE DNA 
methylation and hepatocarcinogenesis in mice.76,77 Furthermore, the differential 
tumorigenic responses of xenotransplanted leukemia cells THP-1 or NB4 exposed to 
either a high-fat or high-carbohydrate diet78, underlines the importance of 
understanding energy metabolism of disease subtypes prior to dietary interventions. 
Furthermore, we uncover a positive correlation between gene body methylation and 
expression in THP-1 cells. That correlation represents the behavior of a majority, but 
not all genes, underlining a complex association between transcription and gene body 
methylation. Similar conclusions have been drawn in several genome-wide studies of 
DNA methylation with recent reports suggesting that gene body methylation increases 
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gene expression levels.79,80 
Methods 
Cell culture 
THP-1 monocytes were cultured in RPMI-1640 medium (Gibco) supplemented with 
2mM L-Glutamine (Sigma), 10% fetal calf serum (Gibco) and 1% 
Penicillin/Streptomycin (Gibco). Cells were never allowed to grow above a 1-1.5x106 
cells/ml concentration. MEFs obtained from SIRT1- or SIRT6-null mice were a kind gift 
from Dr. Raúl Mostoslavsky (Harvard University, Boston, USA) and Dr. Eva Bober 
(MPI, Bad Nauheim, Germany), respectively. SIRT2-null MEFs were generated by 
standard procedures from SIRT2-null mice. WT MEFs were derived from littermates of 
each mutant mice strain. MEFs and HEK293T cells were grown in the same conditions 
as THP-1 monocytes but with DMEM as medium. Pure FAs (Sigma) were conjugated 
with cell culture-grade FA-free BSA (fraction V, FA-free, Sigma no. 820022) to achieve 
a FA:BSA 6:1 ratio, essentially as described.81 Typically, 5-6x106 cells in 10 ml medium 
were stimulated with 100x BSA-FA mix in 2% FCS. Exclusion of trypan blue was used 
as a criterion for viability. The inhibitors etomoxir, GW9662, GW6471, sirtinol, 
splitomycin or trichostatin A (TSA) were used at the concentrations and experimental 
conditions reported in previous studies.82,83 At least three technical and biological 
replicates were performed for each experiment, excluding microarray experiments. 
Global DNA methylation 
DNA was extracted from cultured cells by standard methods (DNeasy system, Qiagen). 
For the measurement of global DNA methylation levels, 5-methyl-2'-deoxycytidine 
(5mdC) and 2'-deoxyguanosine (dG) were determined by an HPLC-based method.84 
Normalized 5mdC levels were calculated as percentage 5mdC/dG. When indicated, 
global DNA methylation was measured by the MethylFlash system (Epigentek). The 
assay yielded 5mdC values as percentage of PicoGreen-quantified input DNA (wt/wt). 
Each value was multiplied by four to obtain a final value comparable to that obtained by 
the HPLC-based method. The MethylFlash assay yielded responses to AA and OA in 
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THP-1 monocytes, that were consistent with the ones obtained by the HPLC-based 
5mdC quantitation, except for baseline (unstimulated cells) values that were 5% lower 
(P>0.05, data corresponding to a total of 15 and 21 experiments, respectively).  
ALU repeat methylation 
ALU element methylation was determined according to Sirivanichsuntorn and 
collaborators.28 Briefly, bisulfite-treated DNA was amplified by PCR with the ALU-
specific primers AluF: 5’-GGY GYG GTG GTT TAY GTT TGT AA-3’ and AluR: 5’-TTA 
ATA AAA ACR AAA TTT CAC CAT ATT AAC CAA AC-3’ as follows: 95°C for 30s, 
53°C for 20s (40 cycles), and 72°C for 20s. Subsequently, the 117 bp ALU amplicon 
was digested overnight at 65°C with TaqI (Invitrogen). The resulting products, ranging 
between 42 and 117 bp depending on the methylation states of ALU elements, were 
separated by gel electrophoresis, stained with GelRed and quantified using ImageLab 
(BioRad).  
DNA methylation arrays 
To identify targets of FA-induced DNA methylation we used the Infinium 
HumanMethylation450 BeadChip platform (Illumina). Three biological replicates were 
pooled in equal proportion for each FA concentration. Pooling effectively averages the 
data and reduces noise.85 DNA quality checks, bisulfite modification, hybridization, data 
normalization with the GenomeStudio software (Illumina) and Beta value calculation 
were carried out as described elsewhere.29,86 SNP-proximal probes and probes with a 
detection P-value >0.05, i.e., not statistically different from the background, were 
discarded as reported.45 The methylation level for each cytosine, expressed as a -
value, was calculated as the fluorescence intensity ratio of methylated to unmethylated 
versions of each probe. Beta values ranged between 0 (unmethylated) and 1 
(methylated). Logit-transformed -values (M-values) were used in statistical tests 
unless indicated.87 or Δβ values were used for data description, due to their more 
intuitive nature. The annotation relating to CpG islands (CGIs) uses the following 
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nomenclature: "shore", each of the 2 kb-sequences flanking a CGI; "shelf", each of the 
2 kb-sequences next to a shore; "open sea", DNA not included in shores, shelves or 
CGIs.29 TSS200 or TSS1500 indicate the region between position -200 bp or -1,500 bp 
and the Transcription Start Site (TSS), respectively. When a cytosine mapped to 
different genic elements due to the presence of multiple alternative transcripts, all 
mapping variants were counted. Functional gene annotation was analyzed with the 
DAVID tool (http://david.abcc.ncifcrf.gov/). 450K array data are accessible in NCBI's 
Gene Expression Omnibus88 with the accession number GSE67331. DNA methylation 
array data of selected CpGs were validated by pyrosequencing (PyroMark Q96 ID, 
Qiagen). Sequences of pyrosequencing primers are shown in Supplementary Table 
6. 
Expression arrays 
Genome expression was analyzed by Human Exon 1.0 ST arrays (Affymetrix) and we 
used the Affymetrix Expression ConsoleTM software (version 1.3) and Robust Multichip 
Average algorithm (RMA) to normalize and analyze array data. The library used was 
the HuEx-1_0-st-v2.r2.pgf with the probe set HuEx-1_0-st-
v2.r2.dt1.hg18.extended.mps (gene level) and HuEx-1_0-st-v2.r2.dt1.hg18.full.mps 
(exon level). Expression array data are accessible in NCBI's Gene Expression 
Omnibus88 with the accession number GSE57076. Validation of selected targets was 
performed by semi-quantitative PCR normalized to GAPDH expression levels. 
Statistics 
The Kruskal-Wallis test was performed to test for differences in DNA methylation levels 
between treatments or doses for continuous variables. If the overall comparison was 
significant, samples were re-analyzed by ANOVA followed by Scheffé's post-hoc test to 
identify specific different groups. When comparing two groups, the Mann-Whitney U 
test (unpaired samples) or the Wilcoxon test (paired samples). The Chi-square test was 
applied to compare percentages. Correlations were tested by calculating the Pearson's 
correlation coefficient and the associated p value. Tests were performed with the 
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Statistica software (StatSoft) or Excel statistics tools (Microsoft Office 2011 for 
Macintosh). The significance of CpG enrichment was estimated with the 
hypergeometric test using an online tool 
(www.geneprof.org/GeneProf/tools/hypergeometric.jsp). 
Abbreviations and acronyms 
450K array, Infinium HumanMethylation450 BeadChip 
5mdC, 5-methyl-2'-deoxycytidine 
AA, arachidonic acid 
AACpG, AA-induced differentially methylated CpG 
CGI, CpG island 
CpG, 5'-CG-3' dinucleotide 
DB-CpG, CpG scored by Δβ 
EPA, eicosapentaenoic acid 
FACpG, differentially methylated CpG common to the AACpG, OACpG and 
PACpG sets 
FDR, false discovery rate 
MEF, mouse embryonic fibroblasts 
N-CpG, number of CpGs normalized by dividing the number of differentially 
methylated CpGs by the total number of CpGs represented in the 450K array for a 
given gene 
OA, oleic acid 
OACpG, OA-induced differentially methylated CpG 
PA, palmitic acid 
PACpG, PA-induced differentially methylated CpG 
PPAR, peroxisome proliferator-activated receptor 
SIRT, sirtuin. Official acronyms were used for all genes. 
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Figure 1 - Effects of pure FAs on global DNA methylation in THP-1 monocytes. A, FA 
dose-response following a 24-hour stimulation. B, co-stimulation with AA and 
OA, in which each FA was held constant at the 100 μM dose (symbols in graph 
A) and the other varied between 1-100 μM (indicated as "variable FA" in the 
horizontal axis legend). Data in A were obtained by the HPLC-based 5mdC 
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Figure 1 - Effects of pure FAs on global DNA methylation in THP-1 monocytes.  A, FA dose-
response following a 24 hour stimulation. B, co-stimulation with AA and OA, in which each FA 
was held constant at the 100 μM dose (symbols in graph A) and the other varied between 1-100 
μM (indicated as "variable FA" in the horizontal axis legend). Data in A were obtained by the 
HPLC-based 5mdC quantitation, data in B by the MethylFlash assay (see text for details). Data 
points represent averages and SD values. The horizontal dashed line indicates the value 
corresponding to unchallenged (control) cells. The latter value differs in panels A and B because 
of the different assays used. C, ALU methylation levels. Symbols are as in A. In all cases, asterisks 
indicate the significance of the difference in comparison with the respective 1 μM dose. 
Horizontal brackets in A indicate the AA or OA doses at which the response is significantly 
different from the response to the vehicle BSA. *, p<0.05; **, p<0.01 (Scheffé post hoc test). 
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quantitation, data in B by the MethylFlash assay (see text for details). Data 
points represent averages and SD values. The horizontal dashed line indicates 
the value corresponding to unchallenged (control) cells. The latter value differs 
in panels A and B because of the different assays used. C, ALU methylation 
levels. Symbols are as in A. In all cases, asterisks indicate the significance of 
the difference in comparison with the respective 1 μM dose. Horizontal brackets 
in A indicate the AA or OA doses at which the response is significantly different 
from the response to the vehicle BSA. *, P<0.05; **, P<0.01 (Scheffé post hoc 
test). 
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Figure 2 – Unsupervised clustering analysis of high-density DNA methylation array 
(450K array)-based analysis of FA dose-dependent CpG methylation. 
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Figure 2 – Unsupervised clustering analysis of high-density DNA methylation array (450k 
array)-based analysis of FA dose-dependent CpG methylation.
 40 
 
 
Figure 3 - Distribution of hypermethylated and hypomethylated AACpGs and OACpGs. 
The AACpG and OACpG sets are ordered for increased Δβ between the two extreme 
FA doses. The horizontal dashed lines indicate the overall average Δβ for each CpG 
set. 
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Figure 3 – Distribution of hypermethylated and hypomethylated AACpGs and 
OACpGs. The AACpG and OACpG sets are ordered for increased Delta-Beta 
between the two extreme FA doses. The horizontal dashed lines indicate the 
overall average Delta-Beta for each CpG set.
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Figure 4 - Examples of locus-specific methylation profiles of AACpGs and OACpGs. 
Graphs on the left show the changes in DNA methylation of AACpGs (solid circles) and 
OACpGs (open squares). P indicates the position and number of CpGs mapping to 
promoters. Graphs on the right show the Δβ values of common CpGs to the AACpG 
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Figure 4 - Examples of locus-specific methylation profiles of AACpGs and OACpGs. Graphs on the left show the 
changes in DNA methylation of AACpGs (solid circles) and OACpGs (open squares). P indicates the position and 
number of CpGs mapping to promoters. Graphs on the right show the Delta-Beta values of common CpGs to the 
AACpG and OACpG sets in each gene or intergenic region. p values refer to unpaired (left) and paired (right) non-
parametric tests (Mann-whitney U test and Wilcoxon test, respectively). 
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and OACpG sets in each gene or intergenic region. P-values refer to unpaired (left) 
and paired (right) non-parametric tests (Mann-Whitney U test and Wilcoxon test, 
respectively). 
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Figure 5 - Clustering analysis of CpGs that are common to AACpG or OACpG or both, 
and to the indicated disease and normal tissue DNA methylation profiles. A, Overall 
data clustering. B, Top 50 genes ranked by the number of harbored CpGs included in 
 44 
 
the clustering analysis. Asterisks indicate the top 11 genes ranked by the number of 
AACpG/gene. Red and blue, hypermethylation and hypomethylation, respectively. The 
tissue origin or relation is indicated for non-normal tissue samples as follows: Ad, 
adipose tissue; Ao, aorta; Bl, blood; Br, brain; In, intestine; Li, liver; Pa, pancreas. 
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Figure 6 - Effects of dose-dependent changes in DNA methylation on gene expression. 
A,  Correlation between 100-1 μM AA or OA Δβ and expression array-based 
corresponding expression levels. B, RT-PCR analysis of selected genes following AA 
and AO stimulation of THP-1 cells for 24 hours at 1 and 100 μM concentration. C, 
GAPDH RNA-normalized expression. The bars for each gene indicate, left to right: 1 
μM AA, 100 μM AA, 1 μM OA, 100 μM OA, respectively.  
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Figure 6 - Effects of dose-dependant changes in DNA methylation on gene expression. A,  Correlation 
between 100 - 1 μM AA or OA Delta-Beta and expression array-based corresponding expression levels. 
B, RT-PCR analysis of selected genes following AA and AO stimulation of THP-1 cells for 24 hours at 1 
and 100 μM concentration. C, GAPDH RNA-normalized expression. The bars for each gene indicate, left 
to right: 1 μM AA, 100 μM AA, 1 μM OA, 100 μM OA, respectively.
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Figure 7 - Participation of PPARs and -oxidation in AA- or OA-induced global DNA 
methylation changes. THP-1 monocytes were stimulated with 100 μM FA for 24 hours 
following a 1 hour  pre-stimulation with inhibitors of -oxidation (etomoxir), PPAR- 
(GW6471) or PPAR-(GW9662). Data are represented as difference in DNA 
methylation between AA and AO-stimulated and unstimulated cells. The corresponding 
inhibitor concentration is indicated (μM). Statistical significance is in comparisons with 
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Figure 7 - Participation of PPARs and beta-oxidation in AA- or OA-induced global DNA methylation 
changes. THP-1 monocytes were stimulated with 100 μM FA for 24 hours following a 1 hour-
prestimulation with inhibitors of beta-oxidation (etomoxir), PPAR-alpha (GW6471) or PPAR-gamma 
(GW9662). Data are represented as difference in DNA methylation between AA and AO-stimulated 
and unstimulated cells. The corresponding inhibitor concentration is indicated (μM). Statistical 
significance is in comparisons with cells grown in the absence of any inhibitor (C). The horizontal 
dashed line indicates the baseline (unstimulated cells) level. For statistics symbols and test, see 
legend of Figure 1.
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cells grown in the absence of any inhibitor (C). The horizontal dashed line indicates the 
baseline (unstimulated cells) level. For statistics symbols and test, see legend of Figure 
1. 
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Figure 8 - Participation of histone deacetylases in AA- or OA-induced global DNA 
methylation changes. A, DNA methylation response in MEFs genetically null for SIRT1, 
-2, or -6 (indicated as "null") and matched WT controls, stimulated with 100 μM AA or 
OA for 24 hours, or unstimulated (U). Statistical significance is in comparison with 
corresponding WT cells. B, Effects of inhibitors of SIRT1 (sirtinol, splitomycin) and 
broad range histone deacetylases (TSA) on the 100 μM AA-induced response. For 
statistics symbols and test, see legend of Figure 1. 
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Figure 8 - Participation of histone deacetylases in AA- or OA-induced global DNA 
methylation changes. A, DNA methylation response in MEFs genetically null for SIRT1, -2 or 
-6 (indicated as "null") and matched WT controls, stimulated with 100 μM AA or OA for 24 
hours, or unstimulated (U). Statistical significance is in comparison with corresponding WT 
cells. B, Effects of inhibitors of SIRT1 (sirtinol, splitomycin) and broad range histone 
deacetylases (TSA) on the 100 μM AA-induced response. For statistics symbols and test, see 
legend of Figure 1.
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